Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032

@inproceedings{Sndergaard2010DifferentialSO,
  title={Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032},
  author={Jonas N S\ondergaard and Ramin Nazarian and Qi Wang and Deliang Guo and Teli Hsueh and Stephen Mok and Hooman Sazegar and Laura E Macconaill and Jordi G Barretina and Sarah M. Kehoe and Narsis Attar and Erika Mar{\'i}a von Euw and Jonathan E. Zuckerman and Bartosz Chmielowski and Begonya Comin-Anduix and Richard Chikara Koya and Paul Mischel and Roger S. Lo and Antoni Ribas},
  booktitle={Journal of Translational Medicine},
  year={2010}
}
Blocking oncogenic signaling induced by the BRAFV600E mutation is a promising approach for melanoma treatment. We tested the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma cell lines. PLX4032 decreased signaling through the MAPK pathway only in cell lines with the BRAFV600E mutation. Seven out of 10 BRAFV600E mutant cell lines displayed sensitivity based on cell viability assays and three were resistant at concentrations up to 10 μM. Among the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 112 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Similar Papers

Loading similar papers…